Amphastar Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AMPH) $55.14 +0.73 (+1.34%) (As of 12:21 PM ET) Add Compare Share Share Today's Range$54.43▼$55.9550-Day Range$44.49▼$57.5252-Week Range$27.58▼$67.66Volume135,339 shsAverage Volume391,269 shsMarket Capitalization$2.64 billionP/E Ratio21.54Dividend YieldN/APrice Target$68.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Amphastar Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside23.4% Upside$68.00 Price TargetShort InterestBearish8.10% of Float Sold ShortDividend StrengthN/ASustainability-2.21Upright™ Environmental ScoreNews Sentiment0.52Based on 4 Articles This WeekInsider TradingSelling Shares$3.67 M Sold Last QuarterProj. Earnings Growth17.87%From $2.91 to $3.43 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.69 out of 5 starsMedical Sector91st out of 949 stocksPharmaceutical Preparations Industry30th out of 440 stocks 2.3 Analyst's Opinion Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $68.00, Amphastar Pharmaceuticals has a forecasted upside of 23.4% from its current price of $55.10.Amount of Analyst CoverageAmphastar Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.10% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently increased by 15.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmphastar Pharmaceuticals has received a 46.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Subcutaneous human immunoglobulin", "Procainamide", "Epinephrine", and "Medroxyprogesterone acetate" products. See details.Environmental SustainabilityThe Environmental Impact score for Amphastar Pharmaceuticals is -2.21. Previous Next 2.5 News and Social Media Coverage News SentimentAmphastar Pharmaceuticals has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest9 people have searched for AMPH on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows11 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 1,000% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,674,930.00 in company stock.Percentage Held by Insiders27.80% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to grow by 17.87% in the coming year, from $2.91 to $3.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 21.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 21.52, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 92.29.Price to Earnings Growth RatioAmphastar Pharmaceuticals has a PEG Ratio of 0.86. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Read More AMPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMPH Stock News HeadlinesNovember 27, 2023 | benzinga.comIndustry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals IndustryNovember 24, 2023 | finance.yahoo.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Delivered A Better ROE Than Its IndustryNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 21, 2023 | americanbankingnews.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard K. Prins Sells 4,000 SharesNovember 21, 2023 | americanbankingnews.comAmphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Lowered by StockNews.comNovember 21, 2023 | finance.yahoo.comInsider Sell Alert: Director Richard Prins Sells 4,000 Shares of Amphastar Pharmaceuticals Inc ...November 20, 2023 | finanznachrichten.deAmphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceNovember 20, 2023 | finance.yahoo.comAmphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 19, 2023 | americanbankingnews.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Short Interest UpdateNovember 19, 2023 | americanbankingnews.comAmphastar Pharmaceuticals (NASDAQ:AMPH) Coverage Initiated by Analysts at Bank of AmericaNovember 18, 2023 | msn.comB of A Securities Initiates Coverage of Amphastar Pharmaceuticals (AMPH) with Neutral RecommendationNovember 17, 2023 | msn.comBofA starts Amphastar at neutral; cites high valuation, Baqsimi prospectsNovember 17, 2023 | realmoney.thestreet.comAmphastar initiated with a Neutral at BofA after 97% year-to-date rallyNovember 17, 2023 | finance.yahoo.comInsider Sell: CFO William Peters Sells Shares of Amphastar Pharmaceuticals IncNovember 16, 2023 | finance.yahoo.comInsider Sell: Director Richard Prins Sells 5,000 Shares of Amphastar Pharmaceuticals Inc (AMPH)November 13, 2023 | finance.yahoo.comWall Street Analysts See Amphastar (AMPH) as a Buy: Should You Invest?November 10, 2023 | finance.yahoo.comAmphastar Pharmaceuticals Stock Earns Composite Rating UpgradeNovember 10, 2023 | markets.businessinsider.comNeedham Keeps Their Hold Rating on Amphastar Pharmaceuticals (AMPH)November 9, 2023 | finance.yahoo.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comQ3 2023 Amphastar Pharmaceuticals Inc Earnings CallNovember 9, 2023 | msn.comAmphastar Pharmaceuticals Non-GAAP EPS of $1.15 beats by $0.46, revenue of $180.6M beats by $6.8MNovember 8, 2023 | finance.yahoo.comAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023November 7, 2023 | msn.comAmphastar Pharmaceuticals Q3 2023 Earnings PreviewNovember 4, 2023 | finance.yahoo.comAmphastar Pharmaceuticals' (NASDAQ:AMPH) 42% YoY earnings expansion surpassed the shareholder returns over the past three yearsNovember 1, 2023 | finance.yahoo.comAmphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023October 31, 2023 | morningstar.comAmphastar Pharmaceuticals Inc AMPHSee More Headlines Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AMPH CUSIPN/A CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees1,615Year FoundedN/APrice Target and Rating Average Stock Price Target$68.00 High Stock Price Target$71.00 Low Stock Price Target$63.00 Potential Upside/Downside+25.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$2.56 Trailing P/E Ratio21.25 Forward P/E Ratio18.70 P/E Growth0.86Net Income$91.39 million Net Margins22.50% Pretax Margin28.48% Return on Equity26.68% Return on Assets13.60% Debt Debt-to-Equity Ratio1.07 Current Ratio2.11 Quick Ratio1.68 Sales & Book Value Annual Sales$498.99 million Price / Sales5.22 Cash Flow$2.26 per share Price / Cash Flow24.05 Book Value$10.94 per share Price / Book4.97Miscellaneous Outstanding Shares47,910,000Free Float34,589,000Market Cap$2.61 billion OptionableOptionable Beta0.87 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Ziping Luo Ph.D. (Age 73)Chairman of the Board, Chief Scientist & COO Comp: $1.53MDr. Yongfeng Zhang Ph.D. (Age 76)Co-Founder, President, CEO, Chief Scientific Officer & Director Comp: $2.13MMr. William J. Peters M.B.A. (Age 55)CFO, Executive VP of Finance, Treasurer & Director Comp: $1.12MMr. Jacob Liawatidewi M.B.A. (Age 49)Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director Comp: $794.15kMr. Rong Zhou M.S. (Age 64)Senior Executive Vice President of Production Comp: $835.05kDan Dischner M.B.A.Vice President of Human Resources & Corporate CommunicationTony Marrs M.B.A.M.P.H., Senior VP of Regulatory Affairs & Clinical OperationsMore ExecutivesKey CompetitorsCorcept TherapeuticsNASDAQ:CORTMoonLake ImmunotherapeuticsNASDAQ:MLTXStructure TherapeuticsNASDAQ:GPCRBausch Health CompaniesNYSE:BHCZai LabNASDAQ:ZLABView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 2,341 shares on 11/24/2023Ownership: 0.045%Public Sector Pension Investment BoardSold 19,736 shares on 11/22/2023Ownership: 0.098%Walleye Capital LLCBought 39,854 shares on 11/21/2023Ownership: 0.082%Comerica BankBought 16,150 shares on 11/21/2023Ownership: 0.033%Jacobs Levy Equity Management Inc.Bought 171,642 shares on 11/17/2023Ownership: 1.158%View All Insider TransactionsView All Institutional Transactions AMPH Stock Analysis - Frequently Asked Questions Should I buy or sell Amphastar Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMPH shares. View AMPH analyst ratings or view top-rated stocks. What is Amphastar Pharmaceuticals' stock price target for 2024? 2 Wall Street research analysts have issued twelve-month target prices for Amphastar Pharmaceuticals' stock. Their AMPH share price targets range from $63.00 to $71.00. On average, they expect the company's stock price to reach $68.00 in the next twelve months. This suggests a possible upside of 23.4% from the stock's current price. View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts. How have AMPH shares performed in 2023? Amphastar Pharmaceuticals' stock was trading at $28.02 at the start of the year. Since then, AMPH stock has increased by 96.6% and is now trading at $55.10. View the best growth stocks for 2023 here. Are investors shorting Amphastar Pharmaceuticals? Amphastar Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 2,890,000 shares, an increase of 15.6% from the October 31st total of 2,500,000 shares. Based on an average daily trading volume, of 450,200 shares, the short-interest ratio is presently 6.4 days. Currently, 8.1% of the company's shares are sold short. View Amphastar Pharmaceuticals' Short Interest. When is Amphastar Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our AMPH earnings forecast. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) posted its quarterly earnings data on Monday, November, 8th. The company reported $0.46 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.22. The business had revenue of $112.20 million for the quarter, compared to analysts' expectations of $103 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 26.68% and a net margin of 22.50%. During the same period last year, the firm posted $0.09 EPS. What ETFs hold Amphastar Pharmaceuticals' stock? ETFs with the largest weight of Amphastar Pharmaceuticals (NASDAQ:AMPH) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Innovator IBD 50 ETF (FFTY), Janus Henderson Small Cap Growth Alpha ETF (JSML), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), ETC 6 Meridian Small Cap Equity ETF (SIXS), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and ERShares NextGen Entrepreneurs ETF (ERSX). What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO? 35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT). Who are Amphastar Pharmaceuticals' major shareholders? Amphastar Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (7.18%), Fuller & Thaler Asset Management Inc. (2.66%), Northern Trust Corp (1.17%), Morgan Stanley (1.17%), Jacobs Levy Equity Management Inc. (1.16%) and Invesco Ltd. (0.86%). Insiders that own company stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi. View institutional ownership trends. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AMPH) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.